In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alberto-Culver sales up 4.5% to $445.4 mil. in first quarter in "tough" environment.

This article was originally published in The Rose Sheet

Executive Summary

ALBERTO-CULVER NET SALES UP 4.5% TO $445.4 MIL. in the first quarter of fiscal 1998 (ended Dec. 31) compared to sales of $426.1 mil. in the same quarter of FY 1997, Alberto-Culver announced Jan. 22. The company attributed a major portion of its growth to the Sally Beauty Company division, which reported a double-digit sales increase. Net earnings rose 17.4% to $19.7 mil. from $16.8 mil. in the year-ago quarter, excluding an after-tax gain of $9.8 mil. in FY 1997 related to an insurance payment following the crash of a corporate airplane. The "increases were achieved in a tough competitive environment and in the face of material impact from lower currency rates internationally," President and CEO Howard Bernick observed at a same-day annual shareholders meeting.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS005063

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel